The Filing Desk

Abeona Therapeutics

ABEO · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ABEO · Last close · November 19, 2026
$2.45
Value Abeona Therapeutics yourself

Abeona Therapeutics reported revenue of $6 million in fiscal 2025. Its operating margin was −1,536.9%. Free cash flow was −$84 million. The diluted share count rose 61.1%.

ABEONA THERAPEUTICS INC. Latest fiscal year ended December 31, 2025 10-K filed March 17, 2026 · 0001493152-26-010413 Updated
Revenue
$6M
 
Operating margin
−1,536.9%
 
Net income
$71M
 
Free cash flow
−$84M
 
Return on equity
70.0%
286.6 pts
Market cap
$142M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-25), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Abeona Therapeutics does

Abeona is a biopharmaceutical company that develops cell and gene therapies for serious genetic diseases. Its one approved product is Zevaskyn, which the FDA approved in April 2025 to treat wounds in children and adults with recessive dystrophic epidermolysis bullosa, a severe inherited skin disease. Zevaskyn is made from a patient's own skin cells, which are modified and grown into sheets that surgeons apply in a single procedure.

The company sells Zevaskyn itself, through a network of qualified treatment centers chosen for their experience with cell and gene therapy. It makes the product at its own factory in Cleveland, Ohio. It says it may seek partners for Zevaskyn and for other products.

Abeona also researches gene therapies for eye diseases, using a new type of viral delivery vehicle, called a capsid, that it licenses. These are still in development and need FDA approval before they can be sold.

Its biggest risks, as it describes them

  • Its income depends on one product, Zevaskyn, and the company has little experience selling a product.
  • It may struggle to make Zevaskyn or to line up enough qualified treatment centers to give it.
  • Clinical studies of its other therapies may be delayed or fail to show they are safe and work.
  • Rules for cell and gene therapies are changing and could make approval harder or slower.
From Abeona Therapeutics's annual report on Form 10-K, filed March 17, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments51525398191
Debt incl. finance leases———1920
Net debt (negative means net cash)———−79−171
Net debt to EBITDA—————
Debt to equity———0.4x0.1x
Interest coverage−24.6x−69.2x−112.8x−15.3x−23.9x
Current ratio3.4x6.8x4.2x6.1x6.9x
Quick ratio3.4x6.8x4.2x6.1x6.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Abeona Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Abeona Therapeutics shares on the open market, and 9 insiders sold $3.5 million, $673,790 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 29, 2026Vishwas SeshadriChief Executive Officer, DirectorSold19,608$5.16$101,177Form 4
Sep 29, 2026Joseph Walter VazzanoChief Financial OfficerSold9,191$5.16$47,426Form 4
Sep 29, 2026Brendan M. O'MalleySVP, Chief Legal OfficerSold6,727$5.16$34,711Form 4
Sep 29, 2026Madhav VasanthavadaChief Commercial OfficerSold4,902$5.16$25,294Form 4
Sep 1, 2026Mark AlvinoDirectorSold15,000$5.86$87,900Form 4
Jul 21, 2026Joseph Walter VazzanoChief Financial OfficerSold1,478$6.53$9,651Form 4
Jul 9, 2026Vishwas SeshadriChief Executive Officer, DirectorSold67,971$6.96$473,078Form 4
Jul 9, 2026Joseph Walter VazzanoChief Financial OfficerSold24,880$6.96$173,165Form 4
Jul 9, 2026Madhav VasanthavadaChief Commercial OfficerSold12,606$6.96$87,738Form 4
Jul 9, 2026Brendan M. O'MalleySVP, Chief Legal OfficerSold12,050$6.96$83,868Form 4
Jun 30, 2026Leila AllandDirectorSold11,000$5.92$65,120Form 4
Jun 15, 2026Christine Berni SilversteinDirectorSold18,160$5.71$103,694Form 4
The latest 12 of 36 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−919.3%——
Altman Z''−38.47−22.51−5.75
Accruals ratio−26.8%−8.9%89.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets——Pass
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPass——
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Abeona Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Abeona TherapeuticsFY25—−1,536.9%−1,448.5%———
DBV TechnologiesFY2535.8%−2,609.2%−2,159.6%———Compare
Korro BioFY25181.5%−1,906.4%−1,237.2%———Compare
CerenomeFY25−10.5%−293.5%−399.8%———Compare
X4 PharmaceuticalsFY25150.0%−1,336.7%−1,317.2%——3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue113—10314—6
Revenue growth−14.5%−5.8%258.2%——−70.0%−52.9%147.5%——
Gross profit—————————4
Research and development11173949303929313427
Operating income−24−28−58−77−81−90−51−47−64−89
Net income−22−27−57−76−84−85−40−54−6471
Diluted EPS (US$)−16.00−16.50−29.75−37.75−22.75−21.50−5.53−2.53−1.551.01
Diluted shares (millions)1222448214166
Cash flow
Cash from operations−13−23−39−63−35−66−44−37−56−76
Capital expenditure0196140028
Free cash flow−14−24−48−69−36−70−44−37−58−84
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation55876935711
Balance sheet at fiscal year end
Cash and short-term investments69138851299551525398191
Debt incl. finance leases————————1920
Total assets111179174223151806464109220
Total liabilities1294045493738496560
Shareholders' equity9917013417810342271544159
Margins and ratios
Gross margin—————————73.7%
Operating margin−2,686.3%−3,325.7%−1,940.2%—−814.2%−2,994.5%−3,600.8%−1,346.7%—−1,536.9%
Net margin−2,460.4%−3,263.9%−1,890.3%—−842.3%−2,831.2%−2,807.4%−1,548.2%—1,223.1%
Free cash flow margin−1,522.3%−2,809.4%−1,612.9%—−363.6%−2,327.2%−3,084.4%−1,066.9%—−1,448.5%
Rule of 40 (growth + FCF margin)−1,536.8%−2,815.3%−1,354.7%——−2,397.2%−3,137.2%−919.3%——
Return on capital——————————
Return on equity−26.2%−20.3%−37.3%−48.8%−60.0%−117.2%−114.8%−260.6%−216.6%70.0%
Return on assets−22.9%−18.9%−32.1%−38.4%−45.0%−73.6%−55.2%−84.5%−73.7%43.3%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Abeona Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Abeona Therapeutics.